Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report.
BACKGROUND
To date, there is no standard treatment for unresectable malignant peritoneal mesothelioma; either best supportive care or systemic chemotherapy with palliative intent are accepted options.


METHODS
Here, we report the case of a 79-year old patient with malignant peritoneal mesothelioma who was treated with pemetrexed single-agent and obtained an impressive long-lasting response.


CONCLUSIONS
Single-agent pemetrexed is a treatment option for malignant peritoneal mesothelioma in selected elderly patients or in patients with unpaired performance status.
Fasola
Gianpiero
G
Dept. of Medical Oncology, University Hospital, P.le S. M. Misericordia, 33100 Udine, Italy. fasola.gianpiero@aoud.sanita.fvg.it
Puglisi
Fabio
F
Follador
Alessandro
A
Aita
Marianna
M
Di Terlizzi
Silvia
S
Belvedere
Ornella
O
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D005971:Glutamates / Q000627:therapeutic use*; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy*; D000068437:Pemetrexed; D010534:Peritoneal Neoplasms / Q000188:drug therapy*
D000964:Antimetabolites, Antineoplastic; D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine